IsoRay (ISR) Reports Q2 Loss of 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
IsoRay Reports Second Quarter Fiscal 2016 Financial Results
February 10, 2016 8:03 AM ESTRICHLAND, Wash., Feb. 10, 2016 /PRNewswire/ --Â IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the second quarter and six months of fiscal 2016, which ended December 31, 2015.
Revenue was $1.19 million for the second quarter of fiscal 2016, which ended December 31, 2015, a 12% increase compared to $1.07 million for the second quarter of fiscal 2015, which ended December 31, 2014. Operating expenses were $1.44 million compared to $0.98 million in the second quarter of... More
